Nivolumab and Stereotactic Ablative Radiation Therapy (SAbR) for Metastatic Clear Cell Renal Cell Carcinoma

NCT02781506 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
7
Enrollment
OTHER
Sponsor class

Stopped Since the treatment landscape for metastatic kidney cancer changed, patients were not becoming eligible for this trial and therefore, the trial was terminated.

Conditions

Interventions

Sponsor

University of Texas Southwestern Medical Center